RE:RE:RE:RE:RE:RE:RE:RE:RE:This is nutsboazklinghorn wrote: Ya if we assume "normal " is 3-4 MM revenue/ quarter then the myth of revenue growth is dead.
CZO has had multi-year revenue declines since 2009 before. The long-term trend has been double digit revenue growth despite temporary declines. Businesses seldomly grow in a straight line for over a decade. Gilles said next year he expects a return to historical trends after the adjustment this year. CZO also has the imminent launch of the oat beta glucan powder with Symrise, and it is working on an avenanthramide powder. The avenanthramide malting technology allowing CZO access to the neutraceutical market can now produce the equivalent of 4 plants from the same input. It has reached commercial scale and could create new opportunity. The 10X PGX scale-up also allows CZO to produce commercial-scale PGX for the first time.